Preventing and treating medication overuse headache
Permanent link
https://hdl.handle.net/10037/12463Date
2017-07-01Type
Journal articleTidsskriftartikkel
Peer reviewed
Abstract
The concept that headache treatment per se may be the cause
of chronification of headache is not new,3 but our understanding
of this concept, and the terminology defining it, have changed
throughout the years. The criteria for MOH are based on expert
consensus rather than formal evidence. According to the current
definition in the latest (2013) International Classification of
Headache Disorders–3 beta, MOH is essentially defined as
headache on 15 days or more per month that is regarded as
a consequence of regular overuse of headache medication in a patient with a pre-existing headache.18 The classification does
not include the number of drug units or dosage used, but the
number of days per month the drug is taken.
Whether medication overuse is a separate secondary
headache rather than a complication of a primary chronic
headache (migraine or tension-type headache)14 is still debated.
Medication overuse headache can occur in patients with
an underlying secondary headache, but only exceptionally.11 All
abortive headache medications taken regularly may lead to
MOH.9,30 However, MOH must not be confused with immediate
or delayed headache secondary to use of, exposure to, or
withdrawal from other substances such as nitroglycerin,
histamine, or caffeine.18
Reducing the dose and eventually discontinuing the overused
medication are the natural first choices of treatment, but experts
differ on the best way to do so. Among patients who manage to
discontinue the overused medication, 50% to 70% will revert to
an episodic headache pattern.9,11
In this Pain Clinical Update, we present MOH as a prevalent
condition with huge individual and societal consequences, focus
on the clinical aspects of this condition, and emphasize that it can
be prevented and treated. This article is based on an unsystematic
search in PubMed for criteria, guidelines, trials, and
reviews of MOH followed by a discretionary selection of
publications. Some of the references used as “clinical evidence
sources” are commented on in the reference list.
Description
Source at: http://doi.org/10.1097/PR9.0000000000000612